Can a common Anti-Inflammatory eye drop slow diabetic vision loss?
NCT ID NCT04505566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether ketorolac, an anti-inflammatory eye drop, can reduce inflammation in the eyes of people with diabetic retinopathy and slow the disease. About 164 adults with type 2 diabetes will use either the active drop or a placebo for up to 3 years. Researchers will measure inflammatory markers and track changes in retinopathy severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ketorolac 0.45% ophthalmic solution (anti-inflammatory eye drop)
What this could lead to
If it works, this could point toward a simple eye drop treatment to slow vision loss from diabetic retinopathy.
What could go wrong
This is an early Phase 1 study with a small number of participants, so results may not apply broadly. The eye drops may not reduce inflammation enough to change disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States